Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
CNS Neurol Disord Drug Targets. 2016; 15(1):45-53.CN

Abstract

INTRODUCTION

Coenzyme Q10 (CoQ10) is an antioxidant that enhances the activity of complex I and II in the Electron Transport Chain. Many preclinical and clinical studies evaluated CoQ10 for neuroprotection against Parkinson's disease (PD). The aim of this study is to synthesize evidence from published randomized controlled trials (RCTs) about the benefit of CoQ10 supplementation for patients with Parkinson's disease.

METHODS

We followed the PRISMA statement guidelines during the preparation of this systematic review and metaanalysis. A computer literature search for (PubMed, EBSCO, Web of science and Ovid Midline) was carried out. We included RCTs comparing CoQ10 with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, UPDRS III and Schwab and England scores were pooled as standardized mean difference (SMD) between two groups from baseline to the endpoint.

RESULTS

Five RCTs (981 patients) were included in this study. The overall effect did not favor either of the two groups in terms of: total UPDRS score (SMD -0.05, 95%CI [-0.10, 0.15]), UPDRS I (SMD -0.03, 95% CI [-0.23, 0.17]), UPDRS II (SMD -0.10, 95%CI [-0.35, 0.15]), UPDRS III (SMD -0.05, 95%CI [-0.07, 0.17]) or Schwab and England score (SMD 0.08, 95%CI [-0.13, 0.29]).

CONCLUSION

CoQ10 supplementation does not slow functional decline nor provide any symptomatic benefit for patients with Parkinson's disease.

Authors+Show Affiliations

Faculty of Medicine, Zagazig University, Zagazig, Egypt. ahmed01251@medicine.zu.edu.eg.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

26553164

Citation

Negida, Ahmed, et al. "Coenzyme Q10 for Patients With Parkinson's Disease: a Systematic Review and Meta-Analysis." CNS & Neurological Disorders Drug Targets, vol. 15, no. 1, 2016, pp. 45-53.
Negida A, Menshawy A, El Ashal G, et al. Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. CNS Neurol Disord Drug Targets. 2016;15(1):45-53.
Negida, A., Menshawy, A., El Ashal, G., Elfouly, Y., Hani, Y., Hegazy, Y., El Ghonimy, S., Fouda, S., & Rashad, Y. (2016). Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. CNS & Neurological Disorders Drug Targets, 15(1), 45-53.
Negida A, et al. Coenzyme Q10 for Patients With Parkinson's Disease: a Systematic Review and Meta-Analysis. CNS Neurol Disord Drug Targets. 2016;15(1):45-53. PubMed PMID: 26553164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. AU - Negida,Ahmed, AU - Menshawy,Ahmed, AU - El Ashal,Gehad, AU - Elfouly,Yasmin, AU - Hani,Yasmein, AU - Hegazy,Yasmin, AU - El Ghonimy,Samar, AU - Fouda,Samar, AU - Rashad,Yomna, PY - 2015/05/28/received PY - 2015/08/18/accepted PY - 2015/11/11/entrez PY - 2015/11/11/pubmed PY - 2016/12/30/medline SP - 45 EP - 53 JF - CNS & neurological disorders drug targets JO - CNS Neurol Disord Drug Targets VL - 15 IS - 1 N2 - INTRODUCTION: Coenzyme Q10 (CoQ10) is an antioxidant that enhances the activity of complex I and II in the Electron Transport Chain. Many preclinical and clinical studies evaluated CoQ10 for neuroprotection against Parkinson's disease (PD). The aim of this study is to synthesize evidence from published randomized controlled trials (RCTs) about the benefit of CoQ10 supplementation for patients with Parkinson's disease. METHODS: We followed the PRISMA statement guidelines during the preparation of this systematic review and metaanalysis. A computer literature search for (PubMed, EBSCO, Web of science and Ovid Midline) was carried out. We included RCTs comparing CoQ10 with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, UPDRS III and Schwab and England scores were pooled as standardized mean difference (SMD) between two groups from baseline to the endpoint. RESULTS: Five RCTs (981 patients) were included in this study. The overall effect did not favor either of the two groups in terms of: total UPDRS score (SMD -0.05, 95%CI [-0.10, 0.15]), UPDRS I (SMD -0.03, 95% CI [-0.23, 0.17]), UPDRS II (SMD -0.10, 95%CI [-0.35, 0.15]), UPDRS III (SMD -0.05, 95%CI [-0.07, 0.17]) or Schwab and England score (SMD 0.08, 95%CI [-0.13, 0.29]). CONCLUSION: CoQ10 supplementation does not slow functional decline nor provide any symptomatic benefit for patients with Parkinson's disease. SN - 1996-3181 UR - https://www.unboundmedicine.com/medline/citation/26553164/Coenzyme_Q10_for_Patients_with_Parkinson's_Disease:_A_Systematic_Review_and_Meta_Analysis_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1871-5273&volume=15&issue=1&spage=45&aulast=Negida DB - PRIME DP - Unbound Medicine ER -